Using cancer's own survival tricks against it, scientists may have found a new way to stay one step ahead of the disease.
Tuesday, NeoGenomics Inc (NASDAQ:NEO) reported fourth-quarter 2023 adjusted EPS of $0.03, a turnaround from a loss of $(0.06), beating the consensus of $(0.02). The company reported sales of $155.55 ...
FT. MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NEO), a leading oncology testing services company, announced today the launch of AML Express, a next-generation sequencing (NGS) assay designed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback